[ad_1]
Hicksville, NY – 
This acquisition, along with the previously announced TWS Pharma acquisition, will make CAN B a contender to become among the leading producers of hemp-based cannabinoid products in America. The addition of Music City Botanicals’ assets adds additional volume in extraction, isomer lab production, and R&D into the evolving isomer market with such products a Delta-10, CBG, CBN, and CBDA. New retail products will include pharmaceutical-grade CBD and related manufactured goods. In-house labeling and packaging now available to the Company will create a chain of custody and compliance process that is uncommon in the industry.
With this acquisition, TN Botanicals is now a complete producer of high-quality CBD products using in-house extraction, distillation, isolate production, and final product fulfillment to complete a vertical chain of custody in all its products. The former MCB executive staff has over one hundred years of combined hemp processing experience in a world-class team of operators, scientists, and salespeople, many of which CAN B intends to engage. Products are manufactured under Good Management Practices, ISO 9000 compliance, and FDA inspected practices inspected. All products are tested by primary and independent third-party labs.
The transaction is valued at well over a million dollars for processing and extraction assets encompassing equipment, inventory, and intellectual property, including all of MCB’s product offerings and trademarks. The Company also intends to lease MCB’s current facility in McMinville, Tennessee, and hire its seasoned and professional employees to produce and sell products under the TN Botanicals LLC division of CANB. The lab is twice the size of CAN B’s Miami operation and has the capacity to produce six hundred liters of quality Delta 8 and other isomers per week.
Marco Alfonsi, Can B’s Chief Executive Officer, commented, “This acquisition brings us additional complementary assets that enable us to control our supply chain from biomass through end products for both retail and wholesale customers. Our previously announced acquisition of TWS Pharma assets will feed this isomer operation and provide us cost synergies and scale. Can B is now a full-service hemp-derived cannabinoid company that can facilitate servicing the large box types as well as the boutique vape and smoke store.”
As part of the asset acquisition, CAN B retains all of the intellectual property including the branding name and retail product lines of MCB. Additionally, CAN B is acquiring a talent pool of seasoned professionals with strong national sales experience in isomer products. The pharmaceutical space will be an important part of the unique formulations that are available within the experienced laboratory staff. The resolute and knowledgeable employee base covers operations in Miami, Tennessee, Colorado, New York, and Washington.
About Can B Corp.
Can B Corp. (OTCQB: CANB) is a health & wellness company providing the highest quality hemp derived cannabinoid products, including under its own brands of Canbiola, Seven Chakras, NuWellness, Pure Leaf Oil and Duramed. Can B utilizes multi-channel distribution to reach consumers, including medical facilities, doctor offices, retailers, online and direct. Can B Corp. operates R&D and production facilities in Lacey, WA, and Florida. To learn more about Can B Corp. and our comprehensive line of high quality products, please visit: Canbiola.com and www.CanBCorp.com, follow Can B Corp on Instagram and Facebook, or visit one of the 1,000+ retail outlets that carry Can B Corp. products.
For more information about Can B Corp., please visit: CanBCorp.com
Forward-Looking Statements
Forward-looking statements and risks and uncertainties discussed in this release contain forward-looking statements. The words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect,” and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of added information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
Investors and Media:
IR@canbiola.com
(917) 658-7878
[ad_2]